NCT03480776

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women With BRCA 1/2 Mutations (STICs and STONEs)

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 117 (actual)
• Sponsor: Canadian Cancer Trials Group · Network
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

While ASA is not a cancer medication, research suggests that taking ASA reduces the probability of getting many types of cancer because of its anti-inflammatory action. Inflammation in the ovaries during ovulation is thought to contribute to the development of ovarian cancer, and, because ASA is an anti-inflammatory medication, it may help to prevent it.

Detailed description

The standard or usual treatment for women with a high risk gene mutation, BRCA1 or BRCA2, is to have risk-reducing surgery to remove the fallopian tubes and ovaries (bilateral salpingo-oophorectomy or bilateral salpingectomy inclusive of fimbria) after they have decided not to have more children naturally. Acetylsalicylic Acid (ASA) is a safe, well tolerated drug taken by mouth. ASA has been available for over 100 years and has been used mainly to relieve fever and pain, but also as an anti-inflammatory medication in order to reduce inflammation (swelling).

Conditions

• Ovarian Cancer Prevention

Interventions

Type	Name	Description
DRUG	Acetylsalicylic acid	81 mg PO daily or 325 mg PO daily
OTHER	Placebo	One tablet PO daily

Timeline

• Start date: 2018-07-24
• Primary completion: 2026-06-30
• Completion: 2026-09-15
• First posted: 2018-03-29
• Last updated: 2026-01-14

Locations

17 sites across 2 countries: Australia, Canada